Chronic hepatitis C: Grading, staging, and searching for reliable predictors of outcome

Human Pathology

Volumn 32, Issue 9, 2001, Pages 899-903

  Koukoulis, George K ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

AGE; ALCOHOL CONSUMPTION; DISEASE COURSE; EDITORIAL; HEPATITIS C; HUMAN; IMMUNE DEFICIENCY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; PROGNOSIS; STAGING; VIREMIA; VIRUS HEPATITIS;

EID: 0034802902     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hupa.2001.28441     Document Type: Article

References (60)

1. Various scoring systems evaluating histological features of chronic hepatitis C treated with interferon
2. Histological grading and staging of chronic hepatitis
3. Chronic hepatitis: Morphology and nomenclature
4. Chronic hepatitis C: The beginning of the end of a time-honored nomenclature?
5. Terminology of chronic hepatitis
6. Classification of chronic viral hepatitis: A need for reassessment
7. The nomenclature of chronic active hepatitis: An obituary
8. Chronic hepatitis: What is activity and how should it be assessed?
9. Classification of chronic hepatitis: Diagnosis, grading and staging
10. Histological grading and staging of chronic hepatitis: Clinical applications and problems
11. Chronic hepatitis. An update on terminology and reporting
12. The nomenclature of chronic hepatitis: Time for a change
13. Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond
14. The role of liver biopsy in hepatitis C
15. Therapy of hepatitis C: Patients with normal aminotransferase levels
16. Hepatitis C: The clinical spectrum of the disease
17. Recovery, persistence and sequelae in hepatitis C virus infection: A perspective on long-term outcome
18. Morbidity and mortality in compensated cirrhosis type C. A retrospective follow-up study of 384 patients
19. The role of liver biopsy in chronic hepatitis C
20. Histological features of cirrhosis with hepatitis C virus for prediction of hepatocellular carcinoma development: A prospective study
21. The long pathological evolution of chronic hepatitis C
22. "Silent killer" or benign disease? The dilemma of hepatitis C virus outcomes
23. Fibrosis in patients with chronic hepatitis C: Detection and significance
24. Long term clinical and histopathological follow-up of chronic posttransfusion hepatitis
25. Long term follow-up of non-A, non-B (type C) post-transfusion hepatitis
26. Natural history of liver fibrosis progression in patients with chronic hepatitis C
27. HCV related fibrosis progression following liver transplantation: Increase in recent years
28. By their scars ye shall know them
29. Clinical outcomes after transfusion-associated hepatitis C
30. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus
31. Fibrosis and other histological features in chronic hepatitis C virus infection: A statistical model
32. The clinical value of grading and staging scores for predicting a long term response and evaluating the efficacy of interferon therapy in chronic hepatitis C
33. Hepatitis activity index is a key factor determining the natural history of chronic hepatitis C
34. Histological features predictive of liver fibrosis in chronic hepatitis C infection
35. Changing views on chronic hepatitis
36. Pathology of hepatitis C virus infection
37. Clinical significance of hepatitis C virus. Genotypes and Quasispecies
38. Assessment of genotype and molecular evolution of hepatitis C virus in formalin-fixed paraffin-embedded liver tissue from patients with chronic hepatitis C virus infection
39. Hepatitis C and alcohol
40. Pathologic diagnosis of chronic hepatitis C: A multicenter comparative study with chronic hepatitis B
41. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3
42. Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas
43. Hepatitis C in the patient with human immunodeficiency virus infection
44. Long term outcome of hepatitis C infection after liver transplantation
45. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation
46. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation
47. Prediction of response to interferon treatment of chronic hepatitis C
48. Factors predictive of a beneficial response to therapy of hepatitis C
49. Factors predictive of response to interferon-β therapy in hepatitis C virus infection
50. Chronic hepatitis C and interferon-β therapy: Predictors of long term response
51. A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in patients with chronic hepatitis C
52. Hepatic iron staining in chronic hepatitis C patients with low HCV RNA levels: A predictive marker for IFN therapy
53. Factors predictive of the response to interferon in patients with chronic hepatitis C
54. Lack of benefit of escalating dosage of interferon-β in patients with chronic hepatitis C
55. Early predictors of response to treatment in patients with chronic hepatitis C
56. Viral and host factors in the prediction of response to interferon-β therapy in chronic hepatitis C after long-term follow-up
57. Therapy of hepatitis C: Overview
58. Efficacy of interferon treatment for patients with chronic hepatitis C: Comparison of response in cirrhotics, fibrotics, or nonfibrotics
59. Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence
60. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon nonresponders